The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes

Takuro Nishikawa, Jiro Inagaki, Yoshihisa Nagatoshi, Reiji Fukano, kentaro nakashima, Nobuhiro Ito, Daisuke Sawa, Yoshifumi Kawano, Jun Okamura

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The impact of a second all-SCT on the long-term outcomes of children who relapse after allo-SCT has been unclear. We retrospectively analyzed the long-term outcomes of different salvage treatments for such children. Sixty-six children with hematological malignancies (40 ALL, 22 AML, three MDS, and one CML) who relapsed after a first allo-SCT received either a second allo-SCT (n = 16) or CTx and/or DLI (n = 50). The median follow-up for all children was 9.1 yr. The five-yr OS after relapse was significantly better in patients who underwent a second allo-SCT (42.9%) than in patients treated with CTx and/or DLI (11.8%) (p < 0.05). However, this advantage diminished with increasing time. The eight-yr OS for these groups of patients were 21.4% and 11.8%, respectively (p = n.s.). Among the 16 patients who received a second allo-SCT, two died more than five yr after the second allo-SCT. A second allo-SCT can therefore lead to a prolonged OS in patients who relapse after allo-SCT. However, a second allo-SCT should be selected carefully. This is because the mortality rate is still high, even when there is an extensive duration of time following the second allo-SCT.

Original languageEnglish
Pages (from-to)722-728
Number of pages7
JournalPediatric Transplantation
Volume16
Issue number7
DOIs
Publication statusPublished - Nov 1 2012

Fingerprint

Hematologic Neoplasms
Recurrence
Therapeutics
Salvage Therapy
Mortality

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT : Long-term outcomes. / Nishikawa, Takuro; Inagaki, Jiro; Nagatoshi, Yoshihisa; Fukano, Reiji; nakashima, kentaro; Ito, Nobuhiro; Sawa, Daisuke; Kawano, Yoshifumi; Okamura, Jun.

In: Pediatric Transplantation, Vol. 16, No. 7, 01.11.2012, p. 722-728.

Research output: Contribution to journalReview article

Nishikawa, T, Inagaki, J, Nagatoshi, Y, Fukano, R, nakashima, K, Ito, N, Sawa, D, Kawano, Y & Okamura, J 2012, 'The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes', Pediatric Transplantation, vol. 16, no. 7, pp. 722-728. https://doi.org/10.1111/j.1399-3046.2012.01737.x
Nishikawa, Takuro ; Inagaki, Jiro ; Nagatoshi, Yoshihisa ; Fukano, Reiji ; nakashima, kentaro ; Ito, Nobuhiro ; Sawa, Daisuke ; Kawano, Yoshifumi ; Okamura, Jun. / The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT : Long-term outcomes. In: Pediatric Transplantation. 2012 ; Vol. 16, No. 7. pp. 722-728.
@article{a51759e5a7f44b998134b36556e0929e,
title = "The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: Long-term outcomes",
abstract = "The impact of a second all-SCT on the long-term outcomes of children who relapse after allo-SCT has been unclear. We retrospectively analyzed the long-term outcomes of different salvage treatments for such children. Sixty-six children with hematological malignancies (40 ALL, 22 AML, three MDS, and one CML) who relapsed after a first allo-SCT received either a second allo-SCT (n = 16) or CTx and/or DLI (n = 50). The median follow-up for all children was 9.1 yr. The five-yr OS after relapse was significantly better in patients who underwent a second allo-SCT (42.9{\%}) than in patients treated with CTx and/or DLI (11.8{\%}) (p < 0.05). However, this advantage diminished with increasing time. The eight-yr OS for these groups of patients were 21.4{\%} and 11.8{\%}, respectively (p = n.s.). Among the 16 patients who received a second allo-SCT, two died more than five yr after the second allo-SCT. A second allo-SCT can therefore lead to a prolonged OS in patients who relapse after allo-SCT. However, a second allo-SCT should be selected carefully. This is because the mortality rate is still high, even when there is an extensive duration of time following the second allo-SCT.",
author = "Takuro Nishikawa and Jiro Inagaki and Yoshihisa Nagatoshi and Reiji Fukano and kentaro nakashima and Nobuhiro Ito and Daisuke Sawa and Yoshifumi Kawano and Jun Okamura",
year = "2012",
month = "11",
day = "1",
doi = "10.1111/j.1399-3046.2012.01737.x",
language = "English",
volume = "16",
pages = "722--728",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT

T2 - Long-term outcomes

AU - Nishikawa, Takuro

AU - Inagaki, Jiro

AU - Nagatoshi, Yoshihisa

AU - Fukano, Reiji

AU - nakashima, kentaro

AU - Ito, Nobuhiro

AU - Sawa, Daisuke

AU - Kawano, Yoshifumi

AU - Okamura, Jun

PY - 2012/11/1

Y1 - 2012/11/1

N2 - The impact of a second all-SCT on the long-term outcomes of children who relapse after allo-SCT has been unclear. We retrospectively analyzed the long-term outcomes of different salvage treatments for such children. Sixty-six children with hematological malignancies (40 ALL, 22 AML, three MDS, and one CML) who relapsed after a first allo-SCT received either a second allo-SCT (n = 16) or CTx and/or DLI (n = 50). The median follow-up for all children was 9.1 yr. The five-yr OS after relapse was significantly better in patients who underwent a second allo-SCT (42.9%) than in patients treated with CTx and/or DLI (11.8%) (p < 0.05). However, this advantage diminished with increasing time. The eight-yr OS for these groups of patients were 21.4% and 11.8%, respectively (p = n.s.). Among the 16 patients who received a second allo-SCT, two died more than five yr after the second allo-SCT. A second allo-SCT can therefore lead to a prolonged OS in patients who relapse after allo-SCT. However, a second allo-SCT should be selected carefully. This is because the mortality rate is still high, even when there is an extensive duration of time following the second allo-SCT.

AB - The impact of a second all-SCT on the long-term outcomes of children who relapse after allo-SCT has been unclear. We retrospectively analyzed the long-term outcomes of different salvage treatments for such children. Sixty-six children with hematological malignancies (40 ALL, 22 AML, three MDS, and one CML) who relapsed after a first allo-SCT received either a second allo-SCT (n = 16) or CTx and/or DLI (n = 50). The median follow-up for all children was 9.1 yr. The five-yr OS after relapse was significantly better in patients who underwent a second allo-SCT (42.9%) than in patients treated with CTx and/or DLI (11.8%) (p < 0.05). However, this advantage diminished with increasing time. The eight-yr OS for these groups of patients were 21.4% and 11.8%, respectively (p = n.s.). Among the 16 patients who received a second allo-SCT, two died more than five yr after the second allo-SCT. A second allo-SCT can therefore lead to a prolonged OS in patients who relapse after allo-SCT. However, a second allo-SCT should be selected carefully. This is because the mortality rate is still high, even when there is an extensive duration of time following the second allo-SCT.

UR - http://www.scopus.com/inward/record.url?scp=84866740451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866740451&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2012.01737.x

DO - 10.1111/j.1399-3046.2012.01737.x

M3 - Review article

C2 - 22694185

AN - SCOPUS:84866740451

VL - 16

SP - 722

EP - 728

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 7

ER -